Subscribe | Sign In

Related Sites

NOTE: By submitting this form and registering with us, you are providing us with permission to store your personal data and the record of your registration. In addition, registration with the Medical Independent includes granting consent for the delivery of that additional professional content and targeted ads, and the cookies required to deliver same. View our Privacy Policy and Cookie Notice for further details.

You can opt out at anytime by visiting our cookie policy page. In line with the provisions of the GDPR, the provision of your personal data is a requirement necessary to enter into a contract. We must advise you at the point of collecting your personal data that it is a required field, and the consequences of not providing the personal data is that we cannot provide this service to you.

Don't have an account? Subscribe

Addition of 177Lu-PSMA-617 to enzalutamide improves PSA-PFS in mCRPC

By Mindo - 19th Nov 2023

Interim results from the phase 2 ENZA-p study (NCT04419402) show that adding 177Lu-PSMA-617 to enzalutamide significantly enhances prostate-specific antigen progression-free survival (PSA-PFS) in patients with metastatic castration-resistant prostate cancer (mCRPC), according to findings presented at the 2023 ESMO Congress.

“This is the first randomised trial combining an androgen receptor signalling inhibitor, enzalutamide, with 177Lu-PSMA-617. It provides strong evidence for an enhanced anti-cancer effect with the combination of enzalutamide and 177Lu-PSMA-617 based on the primary end point, PSA-PFS,” said study co-author Dr Louise Emmett, Director of Theranostics and Nuclear Medicine at St Vincent’s Hospital in Sydney, Australia.

Data from the study showed a median PSA-PFS of 13 months with the combination therapy compared with 7.8 months with enzalutamide alone [HR 0.43; 95% CI, 0.29-0.63; P=.00001]. Median radiographic PFS was 16 months with the combination therapy compared with 12 months for enzalutamide alone [HR 0.67; 95%, CI 0.44-1.01].

Furthermore, PSA 50 per cent (decrease ≥50 per cent from baseline) response rates were 93 per cent (77/83) in the combination arm, compared with 68 per cent (54/79) for enzalutamide alone (P<.001). PSA 90 per cent (decrease ≥90 per cent from baseline) response rates were 78 per cent (65/83) among those in the combination arm compared with 37 per cent (29/79) among those who received enzalutamide alone (P<.001). In total, the ENZA-p study included 162 patients with mCRPC.

Median follow-up among all patients included in the study was 20 months. There is planned follow-up of PFS and overall survival in the study until July 2024.